foxo4-dri p53 FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI 10mg (Proxofim) River Peptides Ltd The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Analysis of the 2 predicted binding pockets of FOXO4 DRI. (A) Surface Download Scientific Diagram
Pay in 4 interest-free payments of $5.65 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3





